Vor Bio price target lowered to $8 from $10 at Oppenheimer
- Oppenheimer analyst Matthew Biegler lowered the firm's price target on Vor Bio to $8 from $10 and keeps an Outperform rating on the shares following the Q3 report. The firm cites updated spending estimates based on guidance from management for the target. It acknowledges Vor's "financial overhang," but still views the company as a "deeply discounted innovator in the biotech sector."
- 11/08/2024
|
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
- CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang.
- 09/30/2024
|
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
- Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg.
- 09/06/2024
|
New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies
- CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.
- 09/05/2024
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 08/28/2024
|
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
- CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update.
- 08/08/2024
|
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,250 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,875 shares of Vor Bio's common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- 08/02/2024
|
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 3,000 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 4,500 shares of Vor Bio's common stock to three newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- 07/09/2024
|
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,000 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,500 shares of Vor Bio's common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- 06/04/2024
|
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
- CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2024, and provided a business update.
- 05/09/2024
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 05/06/2024
|
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 31,750 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 47,625 shares of Vor Bio's common stock to six newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- 05/03/2024
|
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
- CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board.
- 05/02/2024
|
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
- Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 04/04/2024
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 04/01/2024
|
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
- In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
- 03/28/2024
|
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
- CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2023, and provided a business update.
- 03/20/2024
|
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 4,250 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 6,375 shares of Vor Bio's common stock to two newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- 03/05/2024
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 03/04/2024
|
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
- 02/07/2024
|
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of January 29, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 50,000 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 75,000 shares of Vor Bio's common stock to five newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- 02/02/2024
|
Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
- Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.
- 01/19/2024
|
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
- CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced today it has dosed the first patient in VBP301, its Phase 1/2, multicenter, open-label, first-in-human study of VCAR33ALLO. The Company has extended its cash runway into the second half of 2025.
- 01/17/2024
|
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of December 20, 2023, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 2,500 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 3,750 shares of Vor Bio's common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- 12/21/2023
|
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of November 29, 2023 the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 22,875 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 34,313 shares of Vor Bio's common stock to four newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- 12/01/2023
|
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
- CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.
- 11/27/2023
|
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
- CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with acute myeloid leukemia (AML). Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Miami Cancer Institute of Baptist Health South Florida will present these data on November 10, 4:15PM PST, in an oral presentation at the ASTCT/EBMT 6th International Conference on Relapse After Transplant and Cellular Therapy (HSCT²) in Los Angeles, California.
- 11/09/2023
|
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
- CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update.
- 11/07/2023
|
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of October 30, 2023, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 50,000 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 75,000 shares of Vor Bio's common stock to four newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- 11/03/2023
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 11/03/2023
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 09/25/2023
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 08/30/2023
|
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 07/05/2023
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 04/18/2023
|
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
- The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 03/28/2023
|
Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells
- Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells.
- 03/27/2023
|
Vor Bio Announces Q4 And FY 2022 Results
- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported its financial results for the three-month period and full year that ended December 31, 2022, and provided a business update. The post Vor Bio Announces Q4 And FY 2022 Results appeared first on Pulse 2.0.
- 03/24/2023
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 02/21/2023
|
Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference
- CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities' 3rd Annual Oncology Conference.
- 01/12/2023
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 11/22/2022
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 11/01/2022
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 09/06/2022
|
Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect?
- The consensus price target hints at a 298.3% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 09/01/2022
|
Vor Bio to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
- 06/01/2022
|
Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
- Presentations showcase breadth of Vor Bio's multiplex editing capability including base editing of human hematopoietic stem and progenitor cells (HSPCs) enabling new therapeutic approaches following transplant in patients with acute myeloid leukemia (AML) Presentations showcase breadth of Vor Bio's multiplex editing capability including base editing of human hematopoietic stem and progenitor cells (HSPCs) enabling new therapeutic approaches following transplant in patients with acute myeloid leukemia (AML)
- 04/25/2022
|
Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
- CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor's President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference.
- 02/11/2022
|
Vor to Participate in Two Upcoming Investor Conferences
- CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences:
- 01/04/2022
|
Does Vor Biopharma (VOR) Have the Potential to Rally 186% as Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 186.2% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 11/15/2021
|
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
- CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel cell therapy platform at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place in Washington D.C., from November 10-14, 2021.
- 11/09/2021
|
Vor to Participate in Two Upcoming Investor Conferences
- CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor's President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vor's Chief Financial Officer, will be participating in two upcoming virtual investor conferences:
- 11/08/2021
|
Vor to Present New Platform and Preclinical Data at ASH
- CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the upcoming presentation of new data from its novel engineered hematopoietic stem cell (eHSC) platform at the American Society of Hematology (ASH) 63rd Annual Meeting, taking place in Atlanta, Georgia from December 11-14, 2021.
- 11/04/2021
|
Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management
- CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vor's Senior Vice President of Program and Alliance Management. Dr. Schmelmer has more than 25 years of experience leading the development of novel therapies for cancer, autoimmune disorders and infectious diseases at leading biopharmaceutical companies.
- 10/12/2021
|
Vor Biopharma's Lead Hematopoietic Stem Cell Candidate Fast Tracked In US
- The FDA has granted Fast Track designation to Vor Biopharma's (NASDAQ: VOR) VOR33, lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for acute myeloid leukemia (AML). VOR33 consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33.
- 09/09/2021
|
Vor Reports Second Quarter 2021 Financial Results and Provides Company Update
- CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2021, and provided a business update.
- 08/09/2021
|
Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia
- Vor Biopharma Inc (NASDAQ: VOR) has collaborated with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ). Under the terms of the collaboration, Vor Biopharma will investigate the combination of Vor's engineered hematopoietic stem cell (eHSC) platform with one of Janssen's bi-specific antibodies for acute myeloid leukemia (AML).
- 07/08/2021
|
Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
- CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the formation of a collaboration with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation.
- 07/08/2021
|
Vor Biopharma: Targeted Therapies For Transplants
- Vor Biopharma: Targeted Therapies For Transplants
- 06/30/2021
|
Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp
- CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies to be used in combination with targeted therapies for the treatment of cancer, today announced Matthew R. Patterson as Chairman of its Board of Directors.
- 06/11/2021
|
Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences
- CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Robert Ang, MBBS, MBA, Vor's President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vor's Chief Financial Officer, are scheduled to present at the following conferences:
- 05/25/2021
|
Vor Reports Fiscal Year 2020 Financial Results
- IND accepted for VOR33, Vor's lead eHSC product candidate for treatment of AML
- 03/25/2021
|
Vor Biopharma to Present at the Barclays Global Healthcare Conference
- CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Barclays Global Healthcare Conference, which will take place virtually on March 9-11, 2021.
- 03/05/2021
|
Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference
- CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021. Robert Ang, MBBS, MBA, Vor's President and Chief Executive Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are scheduled to present on Thursday, March 4, 2021, at 1:30 p.m. E.T.
- 03/01/2021
|
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
- CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the closing of its previously announced initial public offering of 9,828,017 shares of its common stock, plus an additional 1,474,202 shares sold pursuant to the full option exercised by the underwriters, at a price to the public of $18.00 per share. The aggregate gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, were approximately $203.4 million. The shares began trading on the Nasdaq Global Market on Friday, February 5, 2021 under the ticker symbol “VOR”.
- 02/09/2021
|
VOR Stock Price Increased 108.33%: Why It Happened
- The stock price of Vor Biopharma Inc. (NASDAQ: VOR) increased by 108.33% on Friday, February 5. This is why it happened.
- 02/08/2021
|
U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week
- The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.
- 02/08/2021
|
The Biotech IPO Wave Continues. Here Are 7 Stocks Hitting the Market.
- A flock of biotech companies are opening for trading Friday. Most of the deals grew in size, with price increases as well.
- 02/05/2021
|
Vor Biopharma's stock more than doubles out of the gate
- Shares of Vor BioPharma Inc. blasted out of the gate Friday, as they open at more the double the upsized initial public offering's price. The first trade for the Massachusetts-based cell therapy company's stock was at $42.02 at 11:19 a.m.
- 02/05/2021
|
